原发性甲状旁腺功能亢进症的诊治

doi:10.16138/j.1673-6087.2023.04.018

摘要/Abstract

中图分类号:

R581.1

杨毓莹, 孙立昊, 刘建民. 原发性甲状旁腺功能亢进症的诊治[J]. 内科理论与实践, 2023, 18(04): 297-300.

YANG Yuying, SUN Lihao, LIU Jianmin. Diagnosis and treatment of primary hyperparathyroidism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 297-300.

参考文献 31

[1]	Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism[J]. J Bone Miner Res, 2022, 37(11): 2315-2329. doi: 10.1002/jbmr.4665 pmid: 36245271
[2]	Tao X, Xu T, Lin X, et al. Genomic profiling reveals the variant landscape of sporadic parathyroid adenomas in Chinese population[J]. J Clin Endocrinol Metab, 2023, 108(7): 1768-1775. doi: 10.1210/clinem/dgad002 pmid: 36611251
[3]	Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop[J]. J Bone Miner Res, 2022, 37(11): 2293-2314. doi: 10.1002/jbmr.4677 pmid: 36245251
[4]	Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism[J]. JAMA, 2020, 323(12): 1186-1187. doi: 10.1001/jama.2020.0538 pmid: 32031566
[5]	中国研究型医院学会甲状旁腺及骨代谢疾病专业委员会, 中国研究型医院学会罕见病分会. 甲状旁腺癌诊治的专家共识[J]. 中华内分泌代谢杂志, 2019, 35(5): 361-368.
[6]	陈斯, 张晶晶, 洪天配. 甲状旁腺功能障碍与生殖功能[J]. 中华内分泌代谢杂志, 2021, 37(7): 673-676.
[7]	姚晓爱, 宋秀霞, 修磊, 等. 以抑郁症起病的原发性甲状旁腺功能亢进症一例报道并文献回顾[J]. 中华内分泌代谢杂志, 2021, 37(11): 1009-1012.
[8]	Wang SM, He Y, Zhu MT, et al. The associations of serum osteocalcin and cortisol levels with the psychological performance in primary hyperparathyroidism patients[J]. Front Endocrinol (Lausanne), 2021, 12: 692722. doi: 10.3389/fendo.2021.692722 URL
[9]	He Y, Liu RX, Zhu MT, et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism[J]. EBioMedicine, 2019, 40: 56-66. doi: S2352-3964(18)30561-9 pmid: 30528454
[10]	Yuan TJ, Yang YY, Zhu MT, et al. Association of famine exposure on the changing clinical phenotypes of primary hyperparathyroidism in 20 years[J]. Front Endocrinol (Lausanne), 2022, 13: 907019. doi: 10.3389/fendo.2022.907019 URL
[11]	Kim SJ, Shoback DM. Sporadic Primary Hyperparathyroidism[J]. Endocrinol Metab Clin North Am, 2021, 50(4): 609-628. doi: 10.1016/j.ecl.2021.07.006 URL
[12]	Cusano NE, Cetani F. Normocalcemic primary hyperparathyroidism[J]. Arch Endocrinol Metab, 2022, 66(5): 666-677. doi: 10.20945/2359-3997000000556 pmid: 36382756
[13]	Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype[J]. J Clin Endocrinol Metab, 2007, 92(8): 3001-3005. doi: 10.1210/jc.2006-2802 URL
[14]	Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form:to treat or not to treat?[J]. Endocr Pract, 2016, 22(3): 294-301. doi: 10.4158/EP15704.OR pmid: 26523628
[15]	Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations[J]. J Clin Endocrinol Metab, 2013, 98(7): 2734-2741. doi: 10.1210/jc.2013-1300 pmid: 23690312
[16]	Zhao L, Liu JM, He XY, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center[J]. J Clin Endocrinol Metab, 2013, 98(2): 721-728. doi: 10.1210/jc.2012-2914 pmid: 23365127
[17]	王鸥, 邢小平, 孟迅吾, 等. 原发性甲状旁腺功能亢进症患者骨密度及胫骨超声速率的改变[J]. 诊断学理论与实践, 2006, 5(6): 499-502.
[18]	宋桉, 王鸥, 邢小平. GCM2突变相关原发性甲状旁腺功能亢进症的发病机制及临床特点[J]. 中华内分泌代谢杂志, 2022, 38(5): 437-439.
[19]	Lin X, Fan Y, Zhang Z, et al. Clinical Characteristics of primary hyperparathyroidism: 15-year experience of 457 patients in a single center in China[J]. Front Endocrinol (Lausanne), 2021, 12: 602221. doi: 10.3389/fendo.2021.602221 URL
[20]	Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma[J]. Front Horm Res, 2019, 51: 63-76. doi: 10.1159/000491039 pmid: 30641523
[21]	胡亚, 廖泉. 甲状旁腺癌分子机制研究现状及临床应用前景[J]. 中华内分泌代谢杂志, 2020, 36(6): 537-540.
[22]	张冬雪, 魏伯俊, 姚晓爱, 等. 甲状旁腺肿瘤诊断中两种lncRNA评分模型的构建[J]. 中华内分泌代谢杂志, 2021, 37(12): 1061-1067.
[23]	Chen L, Shan C, Xu S, et al. Single-cell transcriptomic atlas of parathyroid adenoma and parathyroid carcinoma[J]. J Bone Miner Res, 2023, 38(7): 994-1005. doi: 10.1002/jbmr.v38.7 URL
[24]	Schini M, Jacques R, Oakes E, et al. Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium[J]. Eur J Endocrinol, 2021, 184(1): K7-K10. doi: 10.1530/EJE-20-0634 pmid: 33112283
[25]	Yang YY, Zhang D, Ma LY, et al. Association of famine exposure and the serum calcium level in healthy Chinese adults[J]. Front Endocrinol (Lausanne), 2022, 13: 937380. doi: 10.3389/fendo.2022.937380 URL
[26]	Zhu M, He Y, Liu T, et al. Factors that affect the sensitivity of imaging modalities in primary hyperparathyroidism[J]. Int J Endocrinol, 2021, 2021: 3108395.
[27]	Zhang M, Sun L, Rui W, et al. Semi-quantitative analysis of ^99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma[J]. Quant Imaging Med Surg, 2019, 9(8): 1394-1401. doi: 10.21037/qims URL
[28]	何泱, 孙立昊, 刘建民. 原发性甲状旁腺功能亢进症患者即使影像学定位不能确定也应手术探查治疗[J]. 中华内分泌代谢杂志, 2017, 33 (11): 920-922.
[29]	张浩, 贺亮. 定性明确而定位不明确的原发性甲状旁腺功能亢进症不应盲目手术[J]. 中华内分泌代谢杂志, 2017, 33(11): 923-924.
[30]	El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2023, 108(3): 507-528. doi: 10.1210/clinem/dgac621 URL
[31]	姜悦, 王鸥. 地舒单抗在高钙血症治疗中的应用[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15(3): 279-288.

原发性甲状旁腺功能亢进症的诊治

Diagnosis and treatment of primary hyperparathyroidism

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李荣国, 张伟军, 徐婷燕, 杜琪威. 甲状旁腺全切除联合自体前臂移植治疗继发性甲状旁腺功能亢进[J]. 外科理论与实践, 2022, 27(04): 346-350.
[2]	占志朋, 谢席胜, 张凌. 维持性血液透析合并难治性继发性甲状旁腺功能亢进患者甲状旁腺激素水平与骨密度的关系[J]. 内科理论与实践, 2021, 16(01): 45-48.
[3]	单成祥, 李伟, 刘冰洋, 王强, 饶文胜, 查斯洛, 仇明, 张伟. Tider方法在手术治疗继发性甲状旁腺功能亢进中的应用[J]. 外科理论与实践, 2020, 25(03): 234-238.
[4]	杜艳萍, 程群. 骨质疏松症使用甲状旁腺激素类似物和双膦酸盐序贯治疗的机制及策略[J]. 诊断学理论与实践, 2020, 19(03): 219-224.
[5]	李伟, 刘冰洋, 单成祥, 饶文胜, 张伟, 仇明. 甲状旁腺肃清术对继发性甲状旁腺功能亢进的疗效评价[J]. 外科理论与实践, 2019, 24(04): 325-329.
[6]	王红鹰, 黄骏文, 邹强, 陈靖, 张敏敏, 张炜晨, 劳正胤. 甲状旁腺全切除加前臂自体移植术治疗肾性继发性甲状旁腺功能亢进的长期疗效[J]. 外科理论与实践, 2018, 23(06): 523-527.
[7]	王琳, 陈东, 朱峰, 辛明徽, 刘畅, 彭程, 刘强强,. 甲状旁腺次全切除术和西那卡塞口服对难治性甲状旁腺功能亢进患者骨代谢的影响[J]. 内科理论与实践, 2018, 13(06): 364-367.
[8]	冯国伟, 陈刚. ^99mTc-MIBI SPECT/CT甲状旁腺显像发现颈部恶性肿瘤的价值及与超声对比[J]. 诊断学理论与实践, 2018, 17(06): 682-686.
[9]	田滨瑶, 徐天华, 姚丽,. 继发性甲状旁腺功能亢进的治疗与进展[J]. 内科理论与实践, 2018, 13(04): 250-254.
[10]	陈靖,. 慢性肾脏病矿物质和骨异常治疗进展:合理应用维生素D受体激动剂[J]. 内科理论与实践, 2018, 13(04): 207-211.
[11]	张凌, 熊敏,. 肾移植与三发性甲状旁腺功能亢进[J]. 内科理论与实践, 2018, 13(04): 197-201.
[12]	廖泉. 多科合作诊治甲状旁腺功能亢进症[J]. 外科理论与实践, 2018, 23(02): 93-95.
[13]	艾志龙, 王聪. 原发性甲状旁腺功能亢进的诊治策略[J]. 外科理论与实践, 2018, 23(02): 108-111.
[14]	王义增, 何向辉. 原发性甲状旁腺功能亢进症的术前与术中定位[J]. 外科理论与实践, 2018, 23(02): 116-119.
[15]	李富新, 姜若愚, 李东洋, 陈作宇, 魏铭泽, 张柏, 何向辉. 原发性甲状旁腺功能亢进症临床分析（附138例报告）[J]. 外科理论与实践, 2018, 23(02): 125-129.